Probiotic supplements: a private-label overview

Of DAT Supply's six public commercial formats — gummies, sachets, functional jellies, oral strips, liquid drops and pet soft chews — a gut-health concept in the catalogue today ships as a gummy, a sachet or a functional jelly. Capsules and tablets sit outside the published lineup entirely: a useful comparison point when a brand is weighing formats, but not a format DAT Supply manufactures as a private-label order.

Format choice also interacts with the active itself. The catalogue's gummy-format probiotic concept is built on Bacillus coagulans, a strain selected for its ability to hold potency through the gummy production process — a different consideration than a sachet or functional-jelly concept, where the manufacturing route doesn't put the same heat load on the strain. That trade-off is worth raising in a probiotic brief regardless of which format a brand ultimately picks.

DAT Supply groups probiotics inside the Gut Health category, alongside prebiotic fibre and digestive-enzyme concepts — the natural range-mates for a brand building a digestive-support line rather than sourcing a single active in isolation. The category hub is built for brands assembling a gut-routine range, not just one SKU.

Gut-health concepts, including probiotics, typically enter through DAT Supply's personalisation lane rather than the base white-label catalogue path — meaning flavour, format and active-blend adjustments are reviewed against an existing base formulation rather than built from a blank page. That's a faster route to a sample than full custom development, without being locked to an unmodified catalogue SKU.

Beyond the general claims-and-labelling responsibility already covered above, probiotics carry a market-specific wrinkle worth flagging early: permitted health claims for probiotic products are restricted in the EU, and neutral, function-led positioning is the safer starting point for on-pack wording rather than a claim built around a specific health outcome.

This doesn't change who owns the claim decision — the brand owner still signs off on final wording for each destination market — but it does mean a probiotic brief should flag the target market's claim environment early, before flavour and packaging choices lock in around a claim a regulator won't ultimately allow.

Not every gut-health SKU in the catalogue relies on a live bacterial strain. Alongside the live-culture gummy and functional-jelly concepts, the catalogue also carries prebiotic-fibre and postbiotic-forward formulations in sachet and functional-jelly form — an option worth considering when a brand wants digestive-support positioning without the strain-viability considerations that come with a live-culture claim.

This matters for briefing because 'probiotic' and 'gut health' aren't identical categories in the catalogue: a brand set on a specific live strain should say so explicitly, while a brand more interested in general digestive-support positioning has a wider set of prebiotic and postbiotic starting formulas to review before committing to a live-strain format.

A probiotic brief moves fastest when the format decision (gummy, sachet or functional jelly), the strain-versus-fibre direction, and any stability requirement are stated up front, alongside the target market so the claims question above can be scoped at the same time rather than left until label review.

From there, the standard DAT Supply order path applies: a sample is developed against the brief for approval before any production commitment. Brands ready to test a probiotic, prebiotic or postbiotic concept can start a project through the DAT Supply portal or browse the gut-health catalogue directly.